Trial Outcomes & Findings for Compassionate Same-Day Evaluation & Delivery of XRT for Bony Metastasis in Hospice Patients (NCT NCT01760941)

Results Overview

Patient evaluation will consist of surveys conducted at the time of treatment measured by the Radiation Oncologist Evaluation and Feasibility Assessments survey

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

1 participants

Primary outcome timeframe

Up to 6 months

Results posted on

2016-02-29

Participant Flow

Participant milestones

Participant milestones
Measure	Radiotherapy Single fraction radiotherapy Radiotherapy: Single fraction radiotherapy. All study participants will be evaluated, simulated, and treated with conventional single fraction palliative radiotherapy using standard techniques with CT-based treatment. planning.
Overall Study STARTED	1
Overall Study COMPLETED	1
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Compassionate Same-Day Evaluation & Delivery of XRT for Bony Metastasis in Hospice Patients

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Radiotherapy n=1 Participants Single fraction radiotherapy Radiotherapy: Single fraction radiotherapy. All study participants will be evaluated, simulated, and treated with conventional single fraction palliative radiotherapy using standard techniques with CT-based treatment. planning.
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	1 Participants n=5 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants
Sex: Female, Male Female	0 Participants n=5 Participants
Sex: Female, Male Male	1 Participants n=5 Participants
Region of Enrollment United States	1 participants n=5 Participants

PRIMARY outcome

Timeframe: Up to 6 months

Patient evaluation will consist of surveys conducted at the time of treatment measured by the Radiation Oncologist Evaluation and Feasibility Assessments survey

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 2 weeks

Evaluate the treatment influence on the rate of pain stabilization and/or reduction as measured by the validated BPI patient questionnaire.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 2 weeks

Evaluate the treatment influence on patient quality of life as measured by the ESAS.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 6 months

Quantify the percentage of patients receiving the treatment who believe that the treatment was worthwhile

Outcome measures

Outcome data not reported

Adverse Events

Radiotherapy

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Drew Moghanaki, MD, MPH

Virginia Commonwealth University/Massey Cancer Center

Phone: 804-765-5850

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place